A Plus Biotechnology Co., Ltd.
A Plus Biotechnology Co., Ltd. engages in the manufacturing and wholesale of orthopedic and other medical devices. The company offers products for chest, shoulder, spine, elbow, wrist and hand, pelvic and hip, knee, foot and ankle, osteotomy, pediatric and ESF, biologics. It also provides technical support services and labor services. A Plus Biotechnology Co., Ltd. is based in New Taipei City, Ta… Read more
A Plus Biotechnology Co., Ltd. (6918) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.009x
Based on the latest financial reports, A Plus Biotechnology Co., Ltd. (6918) has a cash flow conversion efficiency ratio of 0.009x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$11.02 Million) by net assets (NT$1.25 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
A Plus Biotechnology Co., Ltd. - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how A Plus Biotechnology Co., Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
A Plus Biotechnology Co., Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of A Plus Biotechnology Co., Ltd. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bilendi
PA:ALBLD
|
0.110x |
|
Altisource Portfolio Solutions SA
NASDAQ:ASPS
|
0.005x |
|
Mobiltel Iletisim Hizmetleri Sanayi ve Ticaret AS
IS:MOBTL
|
-0.014x |
|
Taliworks Corporation Bhd
KLSE:8524
|
0.020x |
|
Flat Capital AB Series B
ST:FLAT-B
|
0.000x |
|
GENASYS INC. DL-00001
F:G66
|
N/A |
|
Insas Bhd
KLSE:3379
|
-0.007x |
|
AROBS TRANSILVANIA SOFTWARE SA
RO:AROBS
|
N/A |
Annual Cash Flow Conversion Efficiency for A Plus Biotechnology Co., Ltd. (2021–2024)
The table below shows the annual cash flow conversion efficiency of A Plus Biotechnology Co., Ltd. from 2021 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$919.04 Million | NT$160.96 Million | 0.175x | -8.86% |
| 2023-12-31 | NT$827.94 Million | NT$159.10 Million | 0.192x | +178.16% |
| 2022-12-31 | NT$877.80 Million | NT$60.64 Million | 0.069x | +10.11% |
| 2021-12-31 | NT$843.93 Million | NT$52.95 Million | 0.063x | -- |